Back to Search
Start Over
Complete antithrombin replacement for anticoagulation for cardiopulmonary bypass to repair severe infective mitral valve endocarditis.
- Source :
-
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis [Blood Coagul Fibrinolysis] 2018 Jan; Vol. 29 (1), pp. 123-125. - Publication Year :
- 2018
-
Abstract
- : We present a case of a 26-year-old patient with severe infective endocarditis complicated with cerebral septic emboli that required essentially complete replacement of his circulating antithrombin activity to achieve an activated coagulation time near 480 s. The need for this degree of antithrombin administration may have been secondary to ongoing systemic inflammation and consequent thrombin generation despite blood culture results demonstrating no bacteremia. In sum, ongoing loss of endogenous antithrombin activity secondary to inflammation and the need for more than 80% normal activity to conduct safe cardiopulmonary bypass may require extraordinary administration of exogenous antithrombin in similar settings.
- Subjects :
- Adult
Anticoagulants pharmacology
Antithrombin III pharmacology
Cardiopulmonary Bypass adverse effects
Endocarditis pathology
Humans
Male
Anticoagulants therapeutic use
Antithrombin III therapeutic use
Blood Coagulation Tests methods
Cardiopulmonary Bypass methods
Endocarditis surgery
Mitral Valve surgery
Subjects
Details
- Language :
- English
- ISSN :
- 1473-5733
- Volume :
- 29
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
- Publication Type :
- Academic Journal
- Accession number :
- 28957943
- Full Text :
- https://doi.org/10.1097/MBC.0000000000000668